KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Net Margin (2016 - 2026)

Pfizer has reported Net Margin over the past 18 years, most recently at 0.56% for Q1 2026.

  • Quarterly Net Margin changed N/A to 0.56% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.05% through Mar 2026, up 2.0% year-over-year, with the annual reading at 0.04% for FY2025, 9.0% down from the prior year.
  • Net Margin was 0.56% for Q1 2026 at Pfizer, down from 1.1% in the prior quarter.
  • Over five years, Net Margin peaked at 1.1% in Q2 2025 and troughed at 1.81% in Q3 2024.
  • The 5-year median for Net Margin is 0.03% (2022), against an average of 0.1%.
  • Year-over-year, Net Margin skyrocketed 137bps in 2022 and then tumbled -254bps in 2024.
  • A 5-year view of Net Margin shows it stood at 0.09% in 2022, then tumbled by -716bps to 0.76% in 2023, then plummeted by -139bps to 1.81% in 2024, then surged by 161bps to 1.1% in 2025, then tumbled by -151bps to 0.56% in 2026.
  • Per Business Quant, the three most recent readings for PFE's Net Margin are 0.56% (Q1 2026), 1.1% (Q2 2025), and 1.81% (Q3 2024).